Figure 1: Time To 12-week Confirmed Progression Of Disability (study 1) (Dimethyl Fig1)
This is a graph that shows the percentage of subjects with confirmed progression of disability over a 96-week study period. The study included two groups: a placebo group (n=408) and a group receiving 240mg of dimethyl fumarate delayed-release capsules twice a day (n=409). The percentage of subjects with confirmed progression of disability was 27.1% at baseline and 16.4% at the end of the study.*